Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06402968 · ClinicalTrials.gov registry record

Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage

A clinical trial of Hypertension and Stroke, sponsored by Zeenat Qureshi Stroke Institute.

Recruiting
Registry status
1,000
Enrollment target
9
Study locations

NCT06402968: Recruiting study of Hypertension and Stroke, sponsored by Zeenat Qureshi Stroke Institute.

NCT06402968 is a study of Hypertension and Stroke that is actively recruiting participants, run by Zeenat Qureshi Stroke Institute. The registered enrollment target is 1,000 participants, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (71% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT06402968, a study of Hypertension and Stroke, is actively recruiting participants, sponsored by Zeenat Qureshi Stroke Institute.

RECRUITING
Registry status
1,000 participants
Enrollment target
9
Study locations

Study Summary

The aim is to compare the rate of hypertensive subjects with ICH who reach SBP target with stability within 60 minutes of enrollment, among patients treated with IV clevidipine with those treated with alternate IV antihypertensive regimen.

Primary Outcome

To compare the rate of hypertensive subjects with ICH who reach SBP target with stability within 60 minutes of enrollment, among patients treated with IV clevidipine with those treated with alternate IV antihypertensive regimen. SBP target with stability is defined as achieving a SBP of less than 150 mm Hg and greater than 130 mm Hg with two subsequent consecutive recordings at least 15 minutes apart that show SBP of less than 150 mm Hg and greater than 130 mm Hg.

Interventions

  • DRUG Clevidipine Injection
  • DRUG Alternate IV Antihypertensive Regimen

Study Locations (9)

Texas

  • UT Southwestern Medical Center - Dallas
  • University of Texas Health Science Center San Antonio - San Antonio

California

  • Antelope Valley Medical Center - Lancaster

Florida

  • Cleveland Clinic Martin North Hospital - Stuart

Georgia

  • Augusta University-Neuroscience Center - Augusta

Michigan

  • University of Michigan Health-West - Wyoming

Missouri

  • University of Missouri - Columbia

New York

  • Icahn School of Medicine at Mount Sinai - New York

Ohio

  • Cleveland Clinic Foundation - Cleveland

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2024-06-01
Est. Completion 2028-07-30
Zeenat Qureshi Stroke Institute

1 total trials

What NCT06402968 shows while recruiting

NCT06402968 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (71% lower).

The record links to 3 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Clevidipine Injection is the first listed.

NCT06402968 lists 9 locations in 8 states (Texas, California, Florida).

Frequently Asked Questions

What is clinical trial NCT06402968 about?

NCT06402968 is a clinical study titled "Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage". The aim is to compare the rate of hypertensive subjects with ICH who reach SBP target with stability within 60 minutes of enrollment, among patients treated with IV clevidipine with those treated with alternate IV antihypertensive regimen.

What is the current status of trial NCT06402968?

This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2024-06-01. Estimated completion is 2028-07-30.

What conditions does trial NCT06402968 study?

This clinical trial studies the following conditions: Hypertension, Stroke, Intracerebral Hemorrhage.

What interventions are being tested in trial NCT06402968?

The interventions under investigation include: Clevidipine Injection (DRUG), Alternate IV Antihypertensive Regimen (DRUG).

Who is sponsoring clinical trial NCT06402968?

This trial is sponsored by Zeenat Qureshi Stroke Institute, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06402968 being conducted?

This trial has 9 study locations across California, Florida, Georgia, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06402968's enrollment target sits among peer trials

1,000 65th of 470 higher than 396 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00018044 · 1,000 participants

    Study of Mycobacterial Infections

  • NCT01036581 · 1,000 participants · NA

    Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

  • NCT01192048 · 1,000 participants

    Genetics of Congenital Heart Disease

  • NCT01553214 · 1,000 participants · Phase 4

    Improving White Blood Cell Collection From Healthy Donors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06402968, the US trial registry maintained by the National Library of Medicine. NCT06402968 (large enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.